Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies

SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO).

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.